Diasorin SpA (MIL:DIA) EBIT: €215 Mil (TTM As of Dec. 2025)


MIL:DIA Diasorin SpA MIL:DIA
67 GF Score
Price €66.48
GF Value €90.07
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Diasorin SpA EBIT?

Diasorin SpA MIL:DIA +3.13% 67 EBIT is €215 Mil as of Dec. 2025. GuruFocus rates MIL:DIA with a GF Score™ of 67/100 and a GF Value™ of €90.07 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Diasorin SpA's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was €31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €215 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Diasorin SpA's annualized ROC % for the quarter that ended in Dec. 2025 was 4.59%. Diasorin SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 29.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Diasorin SpA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 5.56%.


Diasorin SpA  (MIL:DIA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Diasorin SpA's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=258.264 * ( 1 - 55.97% )/( (0 + 2475.142)/ 1 )
=113.7136392/2475.142
=4.59 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2873.163 - 189.533 - ( 208.488 - max(0, 505.794 - 785.093+208.488))
=2475.142

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Diasorin SpA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=124.336/( ( (261 + max(0, 0)) + (255.854 + max(328.045, 0)) )/ 2 )
=124.336/( ( 261 + 583.899 )/ 2 )
=124.336/422.4495
=29.43 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(200.702 + 334.604 + 41.299) - (189.533 + 0 + 59.027)
=328.045

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Diasorin SpA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=215.288/3870.781
=5.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diasorin SpA EBIT Related Terms


Diasorin SpA EBIT Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA EBIT Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 421.84 360.55 230.55 270.00 236.08

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 74.00 69.20 57.00 31.08 58.00

MIL:DIA vs TMO, DHR, IDXX: EBIT Comparison

For the Diagnostics & Research subindustry, Diasorin SpA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diasorin SpA EV-to-EBIT vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's EV-to-EBIT falls into.


MIL:DIA
67GF Score
Diasorin SpA MIL:DIA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €215 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €215 Mil mean?
Diasorin SpA (MIL:DIA) has a EBIT of €215 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Diasorin SpA.
Is Diasorin SpA's EBIT too high?
Diasorin SpA's current EBIT is €215 Mil. Overall, Diasorin SpA has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's EBIT compare to TMO and DHR?
Diasorin SpA's EBIT of €215 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Diasorin SpA. Diasorin SpA's current EBIT is €215 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (MIL:DIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €90.07, compared to a current price of €66.48 — trading 26.2% below its estimated fair value. The current EBIT is €215 Mil. Diasorin SpA's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Diasorin SpA (MIL:DIA), the current EBIT is €215 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (MIL:DIA) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €66.48 is trading 26.2% below its estimated GF Value™ of €90.07. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for MIL:DIA:

  • EBIT: €215 Mil
  • GF Value™: €90.07 vs. price of €66.48 (26.2% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the MIL:DIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
67GF Score

Get the complete analysis for MIL:DIA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.48
Price
€90.07
GF Value